2018_Tim Headshot.jpg
Timothy M. Block, Ph.D.

Chairman and Co-Founder

Dr. Block is a Co-Founder of MERNA Sciences and co-inventor of its hepatitis B technologies. He is founder and President of the three inter-related nonprofit organizations - the Pennsylvania Biotechnology Center, Baruch S. Blumberg Institute and Hepatitis B Foundation. With more than 30 years of experience in hepatitis B virus (HBV) and liver cancer research, Dr. Block is an internationally recognized leader in virology and drug discovery. He is co-inventor of HBV antivirals that have reached clinical trials and co-founder of several biotechnology start-up companies, including Synergy Pharmaceuticals. Dr. Block holds 18 patents, is co-author of more than 290 publications, recipient of numerous national honors, a Fellow of the American Association for the Advancement of Science, and an elected member of the U.S. National Academy of Inventors. Prior to joining the Blumberg Institute research faculty fulltime in 2015, he was a tenured Professor at Thomas Jefferson University Medical College (1984-2005) and Drexel University College of Medicine (2005-2015). He continues to serve as an Adjunct Professor at the University of Pennsylvania. Dr. Block will step down in July 2022 from his current responsibilities at the Pennsylvania Biotechnology Center, Baruch S. Blumberg Institute and Hepatitis B Foundation to devote more time to MERNA Sciences.

Loren Danzis, J.D.

Mr. Danzis is a corporate attorney at Fox Rothschild representing emerging growth companies in the fields of software, biotech and commercial space on venture capital financings and M&A.  He is the Board Chair of the Pennsylvania Biotechnology Center and a founder of Delaware Crossing, an angel investor network that has invested in more than 75 companies.  Mr. Danzis serves on the Board of the Hepatitis B Foundation and supports international student exchange programs.

Randall Hyer.jpg
Randall N. Hyer, M.D., Ph.D., M.P.H. 

Chief Executive Officer

Dr. Hyer has more than 15 years of experience in biotechnology with vaccines, biologics, and biosimilars. In November 2021, Dr. Hyer stepped down as Senior Vice President for Global Medical Affairs at Moderna where he worked on the FDA approval and launch of its mRNA COVID-19 vaccine. Prior to Moderna, he headed Clinical Development and Medical Affairs at Dynavax, where he helped achieve approval of HEPLISAV-B, a new two-dose hepatitis B vaccine with a novel adjuvant. He left Moderna to launch MERNA Sciences and brings with him a wealth of development success.